TLDRAbbVie shares rise as VRAYLAR data strengthens its mood disorder treatment case.VRAYLAR real-world studies show gains in depression symptoms and daily function.Bipolar I patients recorded better symptoms, functioning, and quality of life.AbbVie expands VRAYLAR evidence with pediatric safety and comparative research.Patient survey results support adjunctive treatment after weak antidepressant response.AbbVie (ABBV) stock traded at $264.17, up 0.06%, after AbbVie presented new VRAYLAR data at Psych Congress 2026 in New Orleans. The findings covered major depressive disorder and bipolar I disorder through two prospective real-world observational studies involving routine clinical treatment. AbbVie said the results strengthened evidence for VRAYLAR across broader patient groups treated outside tightly controlled clinical trial settings.AbbVie Inc., ABBVVRAYLAR Data Supports Real-World Mood Disorder TreatmentAbbVie presented CReW BP-I results from patients receiving VRAYLAR for bipolar I depression during 12 weeks of routine clinical care. Patients showed improvements in depressive symptoms, everyday functioning, and quality of life during the study period under standard treatment conditions. Researchers also recorded nausea and dizziness as the most common adverse events reported by patients receiving VRAYLAR during treatment.Meanwhile, the ProACt study evaluated adjunctive VRAYLAR in adults with major depressive disorder who had inadequate antidepressant responses in practice. Interim findings showed improvements in depressive symptoms, functioning, motivation, energy, and anhedonia during real-world treatment with adjunctive VRAYLAR. The study focused on patients who continued experiencing symptoms despite receiving existing antidepressant therapy in normal clinical practice settings.These studies extend evidence from controlled trials into broader clinical populations with varied treatment histories, health needs, and daily challenges. Real-world research can show how a medicine performs when clinicians treat patients with more complex profiles outside formal trial settings. Therefore, the findings provide information about VRAYLAR use, effectiveness, and tolerability during everyday psychiatric care for mood disorders.AbbVie Broadens VRAYLAR Research and Treatment EvidenceAbbVie also presented an indirect comparison of cariprazine and lumateperone for adults with major depressive disorder and inadequate antidepressant response. The analysis examined efficacy and safety when clinicians added either medicine to existing antidepressant treatment for patients needing symptom control. AbbVie also released long-term pediatric safety results from an open-label VRAYLAR study covering several psychiatric and developmental conditions.The pediatric study included patients with bipolar I disorder, schizophrenia, or autism spectrum disorder across age groups and treatment periods. Researchers found VRAYLAR generally well tolerated in the groups studied during the longer-term safety and tolerability evaluation. However, cariprazine does not have FDA approval for treating autism spectrum disorder, despite its inclusion in the research program.AbbVie also presented survey findings on treatment preferences after patients experienced an inadequate response to antidepressant therapy. Most respondents preferred adding treatment rather than switching antidepressants, supporting continued demand for adjunctive options. About one in five U.S. adults may experience MDD during their lifetime, while nearly 11 million adults live with bipolar disorder. The post AbbVie Inc. (ABBV) Stock: Surge as VRAYLAR Data Strengthens Mood Disorder Treatment Case appeared first on Blockonomi.